Clinical Chemistry · 2018 · 70 citations · 37 references
MedicineMolecular BiologyMolecular GeneticsCancer GeneticsGenomicsMolecular OncologyCancer BiomarkersCancer GenomicsCancer ImmunotherapyCancer Molecular DiagnosticsMolecular Tumor ProfilingSequencing-based DiagnosticsMicrosatellite Instability AnalysisMicrosatellite Instability AssaysMicrosatellite Instability DetectionMicrosatellite Instability TestingMicrosatellite MarkersMicrosatellite StabilityNext-generation Sequencing-based DetectionTumor Response Evaluation
BACKGROUND: Microsatellite instability (MSI) is an emerging actionable phenotype in oncology that informs tumor response to immune checkpoint pathway immunotherapy. However, there remains a need for MSI diagnostics that are low cost, highly accurate, and generalizable across cancer types. We developed a method for targeted high-throughput sequencing of numerous microsatellite loci with pan-cancer informativity for MSI using single-molecule molecular inversion probes (smMIPs). METHODS: We designed a smMIP panel targeting 111 loci highly informative for MSI across cancers. We developed an analytical framework taking advantage of smMIP-mediated error correction to specifically and sensitively detect instability events without the need for typing matched normal material. RESULTS: Using synthetic DNA mixtures, smMIPs were sensitive to at least 1% MSI-positive cells and were highly consistent across replicates. The fraction of identified unstable microsatellites discriminated tumors exhibiting MSI from those lacking MSI with high accuracy across colorectal (100% diagnostic sensitivity and specificity), prostate (100% diagnostic sensitivity and specificity), and endometrial cancers (95.8% diagnostic sensitivity and 100% specificity). MSI-PCR, the current standard-of-care molecular diagnostic for MSI, proved equally robust for colorectal tumors but evidenced multiple false-negative results in prostate (81.8% diagnostic sensitivity and 100% specificity) and endometrial (75.0% diagnostic sensitivity and 100% specificity) tumors. CONCLUSIONS: smMIP capture provides an accurate, diagnostically sensitive, and economical means to diagnose MSI across cancer types without reliance on patient-matched normal material. The assay is readily scalable to large numbers of clinical samples, enables automated and quantitative analysis of microsatellite instability, and is readily standardized across clinical laboratories.
37
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le, Jennifer N. Durham, Kellie N. Smith et al. · Science · 2017 · 6.6K citations
Life Sciences, Immunology, Oncology +17
C. Richard Boland, Stephen N. Thibodeau, Stanley R. Hamilton et al. · PubMed · 1998 · 4.1K citations
Life Sciences, Genetics, Oncology +17
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio et al. · Genome Medicine · 2017 · 3.7K citations · Full text
Medicine, Cancer Biology, Oncology +17
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen, Diana Miao, Bastian Schilling et al. · Science · 2015 · 3K citations · Full text
Medicine, Cancer Biology, Oncology +17